NCT03309423

Brief Summary

Objective: Arterial blood gas (ABG) is essential in the clinical assessment of potential acutely ill patients venous to arterial conversion (v-TAC), a mathematical method, has recently been developed to convert peripheral venous blood gas (VBG) values to arterialized VBG (aVBG) values. The aim of this study is to test the reliability of aVBG compared to ABG in an intensive care unit (ICU) setting. Method: Consecutive patients admitted to the ICU with pH values \<7,35 or \>7,45 are included in this study. Paired ABG and aVBG samples are drawn from patients via arterial catheter, central venous catheter and/or peripheral venous catheter and compared.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Oct 2017

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 4, 2017

Completed
5 days until next milestone

Study Start

First participant enrolled

October 9, 2017

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 13, 2017

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2018

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 30, 2018

Completed
Last Updated

October 13, 2017

Status Verified

October 1, 2017

Enrollment Period

4 months

First QC Date

October 4, 2017

Last Update Submit

October 12, 2017

Conditions

Keywords

Blood gas analysisCritical carevenus to arterial conversion

Outcome Measures

Primary Outcomes (12)

  • Lin's Concordance correlation coefficient (CCC)

    Comparison of pH between ABG and aVBG (from peripheral venous catheter). The closer CCC is to 1 the better correlation.

    1. january 2018

  • Lin's Concordance correlation coefficient (CCC)

    Comparison of pCO2 (Unit of Measurement: kilopascal) between ABG and aVBG (from peripheral venous catheter). The closer CCC is to 1 the better correlation.

    1. january 2018

  • Lin's Concordance correlation coefficient (CCC)

    Comparison of pO2 (Unit of Measurement: kilopascal) between ABG and aVBG (from peripheral venous catheter). The closer CCC is to 1 the better correlation.

    1. january 2018

  • Lin's Concordance correlation coefficient (CCC)

    Comparison of pH between ABG and aVBG (from central venous catheter). The closer CCC is to 1 the better correlation.

    1. january 2018

  • Lin's Concordance correlation coefficient (CCC)

    Comparison of pCO2 (Unit of Measurement: kilopascal) between ABG and aVBG (from central venous catheter). The closer CCC is to 1 the better correlation.

    1. january 2018

  • Lin's Concordance correlation coefficient (CCC)

    Comparison of pO2 (Unit of Measurement: kilopascal) between ABG and aVBG (from central venous catheter). The closer CCC is to 1 the better correlation.

    1. january 2018

  • Bland and Altman's plot

    Mean difference and 95% limits-of-agreement of pH between ABG and aVBG (from peripheral venous catheter)

    1. january 2018

  • Bland and Altman's plot

    Mean difference and 95% limits-of-agreement of pCO2 (Unit of Measurement: kilopascal) between ABG and aVBG (from peripheral venous catheter).

    1. january 2018

  • Bland and Altman's plot

    Mean difference and 95% limits-of-agreement of pO2 (Unit of Measurement: kilopascal) between ABG and aVBG (from peripheral venous catheter).

    1. january 2018

  • Bland and Altman's plot

    Mean difference and 95% limits-of-agreement of pH between ABG and aVBG (from central venous catheter).

    1. january 2018

  • Bland and Altman's plot

    Mean difference and 95% limits-of-agreement of pCO2 (Unit of Measurement: kilopascal) between ABG and aVBG (from central venous catheter).

    1. january 2018

  • Bland and Altman's plot

    Mean difference and 95% limits-of-agreement of pO2 (Unit of Measurement: kilopascal) between ABG and aVBG (from central venous catheter).

    1. january 2018

Secondary Outcomes (6)

  • Number of patients with sepsis group.

    1. january 2018

  • Number of patient with metabolic disease

    1. january 2018

  • Number of patient with acute respiratory insufficiency

    1. january 2018

  • Mean number of days until pH neutrality in sepsis group

    1. january 2018

  • Mean number of days until pH neutrality in patients with metabolic disease.

    1. january 2018

  • +1 more secondary outcomes

Study Arms (3)

Respiratory disease

Patients with acute respiratory insufficiency admitted to the ICU and with pH \<7,35 or \>7,45

Diagnostic Test: venous to arterial conversion (v-TAC)

Metabolic disease

Patients with acute metabolic disease admitted to the ICU and with pH \<7,35 or \>7,45

Diagnostic Test: venous to arterial conversion (v-TAC)

Sepsis

Patients with acute sepsis admitted to the ICU and with pH \<7,35 or \>7,45

Diagnostic Test: venous to arterial conversion (v-TAC)

Interventions

Venous to arterial conversion (v-TAC) is a software (Obimedical, Denmark), which can convert venous blood gas values to arterial blood gas values. The principle of the method is a mathematical transformation of VBG values to arterialized values (aVBG) by simulating the transport of blood back through the tissue. To facilitate this simulation the following physiologically relevant assumptions were made: 1) The peripheral extremity was well perfused; 2) change in base excess across the tissue sampling site was approximately zero; 3) the respiratory quotient (rate of CO2 production and O2 utilisation over capillaries) could not vary outside the range 0.7 and 1.0, and 4) the haemoglobin concentration was constant from artery to vein.

Metabolic diseaseRespiratory diseaseSepsis

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients admitted to the ICU with acid-base and oxygenation parameters outside the normal reference values.

You may qualify if:

  • All patients admitted to the intensive care with the following:
  • Arterial catheter for other purpose.
  • Peripheral venous catheter or central venous catheter for other purpose.

You may not qualify if:

  • Normal pH in arterial blood gas.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine, Doctoral School, Ph.d. study

Aalborg, North Denmark, 9000, Denmark

RECRUITING

MeSH Terms

Conditions

Respiratory InsufficiencyMetabolic DiseasesAcidosisAlkalosisSepsisAbdomen, Acute

Condition Hierarchy (Ancestors)

Respiration DisordersRespiratory Tract DiseasesNutritional and Metabolic DiseasesAcid-Base ImbalanceInfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsAbdominal PainPainNeurologic ManifestationsSigns and SymptomsSigns and Symptoms, Digestive

Study Officials

  • Peter Leutscher

    Professor, Center for Clinical Research

    STUDY DIRECTOR

Central Study Contacts

Mads Lumholdt

CONTACT

Kjeld Damgaard

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

October 4, 2017

First Posted

October 13, 2017

Study Start

October 9, 2017

Primary Completion

January 30, 2018

Study Completion

March 30, 2018

Last Updated

October 13, 2017

Record last verified: 2017-10

Data Sharing

IPD Sharing
Will not share

IPD will be stored in safe government controlled data drives and paper data will be stored in a secure office. Doors to this office will be closed when investigators are not present. Sensitive IPD will not be shared with external researchers.

Locations